Immunotech Laboratories Appoints New Chief Financial Advisor to Strengthen Company's Growth and International Expansion Plan

PASADENA, Calif., Feb. 7, 2013 /PRNewswire/ --

Immunotech Laboratories, Inc. (PINKSHEETS : IMMB )

Immunotech Laboratories, Inc., today announced the appointment of Mr. Valentin Dimitrov to the company Board of Directors as Chief Financial Advisor effective immediately.

Mr. Dimitrov (48) has an impressive professional history in the International Pharmaceutical World along with an impressive background in the formation and management of International Corporations, including the founding member and supervisory Board Chairman of the International Orthodox Bank – (present "Investbank" JSC).

Immunotech Director Bo Linton, further commented Mr. Dimitrov has an extensive knowledge of the Immunotech "IPF" patented technology and has worked alongside the company for several years, assisting with International awareness and potential Clinical Trial progression for the company's Immunotherapy Treatments.

Immunotech President Harry Zhabilov commented, "We are very pleased to announce the appointment of Valentin to the Board of Directors and feel he will be a valuable member of our team, and significantly help accelerate the progression of the company towards FDA approval for the 'IPF' technology."

The appointment of Mr. Dimitrov to Immunotech's Board of Directors helps with the potential goal of upgrading the company to the NASDAQ exchange, where a minimum of 5 Board Members are required.

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Company Contact:
[email protected]

Investor Relations:
The Nabors Group: 713-875-9200
E-mail: [email protected]
www.facebook.com/Naborsgroup  

CSNNewswire – Be Seen
www.csnnewswire.com

SOURCE Immunotech Laboratories, Inc.